Journal Mobile Options
Table of Contents
Vol. 69, No. 5, 2008
Issue release date: May 2008
Horm Res 2008;69:295–300
(DOI:10.1159/000114861)

Reproducibility of Serum Leptin, Insulin-Like Growth Factor-I, and Insulin-Like Growth Factor-Binding Protein-3 Measurements

Chia V.M. · Newcomb P.A. · White E. · Zheng Y. · Potter J.D. · Lampe J.W.
aCancer Prevention Program, Fred Hutchinson Cancer Research Center, and bDepartment of Epidemiology, University of Washington, Seattle, Wash., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Many epidemiologic studies examine the effects of single measurements of hormones, including those related to obesity such as insulin-like growth factors (IGFs) or leptin, on disease associations; however, few studies have determined whether these single values accurately reflect measurements over time. Methods: We examined the reproducibility of hormones associated with obesity, specifically leptin, IGF-I, and IGF-binding protein-3 (IGFBP-3). Two fasting blood samples, approximately four months apart, were collected from 38 participants from the Seattle metropolitan area; leptin, IGF-I, and IGFBP-3 concentrations were measured in previously unthawed serum samples. Unadjusted and adjusted intraclass correlation coefficients (ICC) were calculated to assess reproducibility. Results: Adjusting for age and sex, the ICCs for leptin, IGF-I, and IGFBP-3 were 0.73, 0.83 and 0.60, respectively. Weighted kappas yielded similar results. Conclusion: These data suggest that for leptin, IGF-I, and IGFBP-3, a single fasting serum measurement can fairly reliably reflect the hormonal milieu over periods of months.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Ren J: Leptin and hyperleptinemia: from friend to foe for cardiovascular function. J Endocrinol 2004;181:1–10.
  2. Kaplan RC, Strickler HD, Rohan TE, Muzumdar R, Brown DL: Insulin-like growth factors and coronary heart disease. Cardiol Rev 2005;13:35–39.

    External Resources

  3. Gola M, Bonadonna S, Doga M, Giustina A: Clinical review: growth hormone and cardiovascular risk factors. J Clin Endocrinol Metab 2005;90:1864–1870.
  4. Somasundar P, McFadden DW, Hileman SM, Vona-Davis L: Leptin is a growth factor in cancer. J Surg Res 2004;116:337–349.
  5. Giovannucci E: Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 2003;35:694–704.
  6. Mills PJ, Ziegler MG, Morrison TA: Leptin is related to epinephrine levels but not reproductive hormone levels in cycling African-American and Caucasian women. Life Sci 1998;63:617–623.
  7. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563–566.
  8. Goodman-Gruen D, Barrett-Connor E: Epidemiology of insulin-like growth factor-I in elderly men and women: The Rancho Bernardo Study. Am J Epidemiol 1997;145:970–976.
  9. Milani D, Carmichael JD, Welkowitz J, Ferris S, Reitz RE, Danoff A, Kleinberg DL: Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab 2004;89:2271–2274.
  10. Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE: Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomarkers Prev 2006;15:972–978.
  11. DSL-10-23100 ACTIVE Human Leptin Enzyme-Linked Immunosorbent (ELISA) Kit, Package insert, July 2003.
  12. DLS-10-2800 ACTIVE Non-Extraction IGF-I Enzyme-Liked Immunosorbent Assay (ELISA) Kit, Package insert, April 2004.
  13. DSL-10-6600 ACTIVE IGFBP-3 Enzyme-Liked Immunosorbent Assay (ELISA) Kit, Package insert, July 2003.
  14. Fleiss JL: The Design and Analysis of Clinical Experiments. New York, Wiley, 1986.
  15. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE: Reproducibility of plasma hormone levels in postmenopausal women over a 2–3-year period. Cancer Epidemiol Biomarkers Prev 1995;4:649–654.
  16. Rosner B: Fundamentals of Biostatistics, ed 5. Pacific Grove, Duxbury Press, 2000.
  17. Fleiss JL, Levin B, Paik MC: Statistical Methods for Rates and Proportions, ed 3. Hoboken, Wiley, 2003.
  18. Armstrong BK, White E, Saracci R: Principles of Exposure Measurement in Epidemiology. Oxford, Oxford University Press, 1992.
  19. Liu J, Askari H, Dagogo-Jack S: Reproducibility of fasting plasma leptin concentration in lean and obese humans. Endocr Res 1999;25:1–10.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50